Effects of Radiotherapy Determined by 11C-methyl-L-methionine Positron Emission Tomography in Patients with Primary Cerebral Malignant Lymphoma
Overview
Affiliations
Two cases of histologically proven primary cerebral malignant lymphoma were examined serially with positron emission tomography (PET) using 11C-methyl-L-methionine (11C Met). Lesions delineated by 11C Met accumulation extended beyond enhancing areas on either X-ray computed tomography (CT) or magnetic resonance imaging. High uptake of 11C Met accurately showed biologically active and residual tumours, at a time when disappearance of a contrast-enhancing lesion on CT seemed to indicate involution. PET provides valuable information on the extent of tumour and assessment of radiotherapy in malignant lymphoma.
PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan.
Kaneta T Jpn J Radiol. 2020; 38(4):343-357.
PMID: 32043236 DOI: 10.1007/s11604-019-00901-8.
Challapalli A, Aboagye E Front Oncol. 2016; 6:44.
PMID: 26973812 PMC: 4770188. DOI: 10.3389/fonc.2016.00044.
Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm.
Yamane T, Sakamoto S, Senda M Eur J Nucl Med Mol Imaging. 2009; 37(4):685-90.
PMID: 19915838 DOI: 10.1007/s00259-009-1302-y.
Positron emission tomography in patients with primary CNS lymphomas.
Roelcke U, Leenders K J Neurooncol. 1999; 43(3):231-6.
PMID: 10563428 DOI: 10.1023/a:1006202402010.
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
Rigo P, Paulus P, Kaschten B, Hustinx R, Bury T, Jerusalem G Eur J Nucl Med. 1996; 23(12):1641-74.
PMID: 8929320 DOI: 10.1007/BF01249629.